2024 Ecog 3311 jco

Ecog 3311 jco

Author: iisi

August undefined, 2024

WebJun 4, 2024 · ECOG Performance Status Scale – ... (University of Maryland Marlene & Stewart Greenebaum Cancer Center) presented the data at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. E3311study chair Barbara Burtness, MD (Yale Cancer Center), highlighted the trial in a May 2024 interview with VJ Oncology. ... WebSep 3, 2024 · A much larger randomized trial, ECOG-ACRIN 3311, tested a precision oncology approach to HPV-positive HNC, driven by pathologic findings at the time of surgical resection. 17 Patients with low-risk features (T1-2, N0-1, clear margins [≥ 3 mm], no extranodal excision [ENE] or perineural invasion [PNI]/lymphovascular invasion [LVI]) …

Biomarker-Driven Radiation Therapy Dose Reduction After …

WebJan 10, 2024 · Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: … WebMay 24, 2024 · Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. A two-year PFS is of particular interest to compare to historical data (ECOG 3311), this specific estimate and its 95% confidence interval will be estimated from the Kaplan-Meier curve and compared descriptively to the same estimate from ECOG 3311 Arm B. albanta letra

Treatment de‐escalation in HPV‐positive oropharyngeal …

WebECoG tests measure electrical potentials generated in the cochlea, a part of the inner ear, in response to audio stimulation. During an ECoG test: A sticker electrode is placed on the … WebOct 26, 2024 · E3311 is a phase II randomized trial of reduced- or standard-dose postoperative RT for resected stage III-IVa (American Joint Committee on Cancer … albanta significado

E1308: Phase II Trial of Induction Chemotherapy Followed by ... - PubMed

The results of the Eastern Cooperative Oncology Group …

WebFeb 15, 2024 · Another effort to explore the de-intensification of adjuvant therapy following robotic surgery of oropharynx cancer is addressed by a clinical trial (ECOG 3311) that is currently open at MSK. WebApr 29, 2024 · We have the concept of de-intensification of therapy for good prognosis. HPV-positive disease [research] was getting started, and whether that was safe, and how to do that was launching clinical trials. The ECOG 3311 trial [NCT01898494] that we published a couple months ago, 2 was just being designed in 2011 or 2012. albanta barilocheWebECOG-ACRIN is supported primarily through National Cancer Institute research grant funding, but also receives funding from private sector organizations through philanthropy … albanta piscologos

"WebThe results of the Eastern Cooperative Oncology Group (ECOG) 3311 clinical trial. The trial included 353 oropharynx carcinoma patients with cT1-2 stage III/IV AJCC7 without matted neck nodes... " - Ecog 3311 jco

Ecog 3311 jco

Treatment de-escalation for HPV-associated oropharyngeal …

WebMay 20, 2024 · Similar results were seen in a randomized phase 2 trial led by Dr. Yom, called NRG HN002. Several trials have also tested deintensification approaches … WebOct 26, 2024 · The Eastern Cooperative Oncology Group (ECOG) 3311 (NCT01898494) study was a RCT for the de-escalation of adjuvant treatment after transoral surgery (TOS) and neck dissection for HPV+ OPSCC (27 ...

Did you know?

WebECOG-3311 [15, 16]. Methods/design The objectives of this trial are to: 1. Compare OS relative to historical controls for de-intensified primary radiotherapy [60Gy±chemo-therapy] versus TOS and neck dissection [± adju-vant 50Gy radiotherapy] in patients with early T-stage HPV+ squamous cell carcinoma of the oropharynx. 2. WebJul 29, 2024 · The overall intent of E3311, which validated a less intense treatment for certain patients with human papillomavirus-positive (HPV+) throat cancer, was to gather essential data for the design of a future, randomized phase III …

WebMar 13, 2014 · The ECOG 3311 is a phase II trial in which patients with stage III and IVa p16-positive OPSCC treated by transoral surgery and neck dissection are stratified into 4 arms according to their pathological results. Patients staged as T1-T2/N0-N1 with negative margins undergo exclusively transoral surgical (ARM A). WebJul 29, 2024 · ECOG-ACRIN to Conduct Randomized Phase III Trial Based on Recent Results of Phase II Study E3311 The overall intent of E3311, which validated a less …

WebJul 12, 2013 · Go to Brief Summary: This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. WebJun 6, 2024 · ECOG-ACRIN plans to pursue the current data with a randomized phase three trial of transoral robotic surgery (TORS)-based treatment compared with conventional chemotherapy and radiation. ... The American Society of Clinical Oncology (#ASCO20) highlighted these results at this year’s annual meeting. “Transoral resection followed by …

WebFeb 10, 2024 · Purpose Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is treatment-responsive. Definitive chemoradiation results in high cure rates but causes long-term toxicity and may represent overtreatment of some patients. This phase II trial evaluated whether complete cli …

WebThe diverse scientific perspectives of our world-class team inform a unique approach to generate the next generation of safe and effective therapeutics for cancer and beyond. Leadership Mani Mohindru, PhD Chief Executive Officer, Board Member Michael Lyman, PhD Sr. Vice President, Research and Development Pallavi Tawde, PhD albanta luis eduardo auteWebJul 12, 2013 · ECOG-ACRIN Cancer Research Group: ClinicalTrials.gov Identifier: NCT01898494 Other Study ID Numbers: E3311 NCI-2013-00814 ( Registry Identifier: … albanta srlWebJun 4, 2024 · E3311 is a phase II randomized study that showed that low-dose radiation at 50 Gy without chemotherapy following transoral surgery (TOS) led to very high survival … alban traviahttp://www.otolaryngology.pitt.edu/people/robert-l-ferris-md-phd-facs albanta vilaboaWebSep 8, 2015 · ECOG 3311 examines the role of transoral eHNS to reduce toxicity in patients with intermediate-risk stage III/IV HPV-associated (p16-positive) OPC, whereas RTOG 1221 explores the role of surgery to intensify locoregional therapy with up-front surgery in poorer prognosis high-risk p16-negative OPC. alban trompette montaiguWeb•ECOG 1308 • HPV + patients • Induction chemo with deintensification of RT for cCR • For cCR (70% of patients) 2 yr PFS and OS of 96% and 96% in patients <10 Pack ... ECOG 3311 Schema. HPV Stratification Studies: Surgical •ADEPT •Adjuvant De-escalation, Extracapsular Spread, P16+, Transoral (ADEPT) •Patients can randomize ... alban trompetteWebOct 17, 2024 · As co-chair of the ECOG H&N committee, Dr. Ferris is leading two prospective randomized trials. ECOG 3311 (accrual 268/515) investigates the potential for surgical deintensification through reduced radiation dose in HPV+ oropharyngeal cancer patients treated with transoral robotic or laser surgery. alban tire lorton